ARTICLE | Distillery Therapeutics
Therapeutics: Bcl-XL
April 2, 2015 7:00 AM UTC
Rodent studies suggest a selective Bcl-XL inhibitor could treat solid tumors without the hematological side effects of navitoclax. Chemical synthesis and in vitro binding studies identified a lead com...